TEGSEDI
Peakinotersen sodium
NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEGSEDI (inotersen sodium) is an antisense oligonucleotide administered subcutaneously for the treatment of hereditary transthyretin (hATTR) amyloidosis in adults. The drug works by reducing transthyretin (TTR) protein production, thereby slowing disease progression in patients with this rare, progressive neurodegenerative disorder.
$6.0MPart D
Peak5.0 years to LOEEarly-stage peak sales in a niche rare disease setting with limited Medicare utilization, indicating small commercial and patient support teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.